메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
안수경 (경민대학교 e-비지니스경영과) 차재빈 (경민대학교)
저널정보
경희대학교 경영연구원 의료경영학연구 의료경영학연구 제17권 제2호
발행연도
2023.6
수록면
1 - 12 (12page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
This study aims to analyze the impact of R&D investment on the financial performance of pharmaceutical companies. Specifically, it examines whether the criteria of R&D investment spanning 4 years or more is appropriate and investigates the influence of current-period R&D investment on financial performance. The sample was extracted from the manufacturing center of medical substances and pharmaceuticals listed on the Korea Exchange (KRX) KOSPI (Korea Composite Stock Price Index) market. A total sample of 1,587 domestic pharmaceutical companies was analyzed for R&D investment in the previous year, centering on the current year's ordinary income for each of the eight years. As expected in hypothesis (H1), the results showed that R&D investment in the short term could not affect the financial performance of the year. Linear regression analysis was conducted to identify the variables that affect ordinary profit. Short-term R&D investment seems to have a negative (-) negative impact on a company's financial performance, but long-term continuous reinvestment has a positive (+) impact on financial performance. As hypothesized (H2), it is expected that pharmaceutical companies need to invest in R&D for an average period of more than 4 years. This investment is crucial as it allows the completion of research and development products, leading to sales or the acquisition of legal rights as intangible assets. Such outcomes can have a significant impact on the future financial performance of the company. It states that the study suggests that companies anticipate the commercialization of new drug developments and the generation of profits for the company once the R&D investment period concludes. The sentence is clear and concise, conveying the expectation of financial gains from the completion of the R&D phase. A limitation of this study is that it may be deemed insufficient from the perspective of accounting information users to solely focus on research and development expenses within the pharmaceutical industry.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0